ResMed Inc. (LON:0KW4)
277.94
+3.56 (1.30%)
At close: Oct 3, 2025
ResMed Revenue
In the fiscal year ending June 30, 2025, ResMed had annual revenue of $5.15B USD with 9.84% growth. ResMed had revenue of $1.35B in the quarter ending June 30, 2025, with 10.20% growth.
Revenue
$5.15B
Revenue Growth
+9.84%
P/S Ratio
8.03
Revenue / Employee
$485.50K
Employees
10,600
Market Cap
30.16B GBP
Revenue Chart
* This company reports financials in USD.
Revenue History
Fiscal Year End | Revenue | Change | Growth |
---|---|---|---|
Jun 30, 2025 | 5.15B | 461.03M | 9.84% |
Jun 30, 2024 | 4.69B | 462.30M | 10.95% |
Jun 30, 2023 | 4.22B | 644.87M | 18.02% |
Jun 30, 2022 | 3.58B | 381.30M | 11.93% |
Jun 30, 2021 | 3.20B | 239.81M | 8.11% |
Jun 30, 2020 | Upgrade Pro | Upgrade Pro | Upgrade Pro |
Jun 30, 2019 | Upgrade Pro | Upgrade Pro | Upgrade Pro |
Jun 30, 2018 | Upgrade Pro | Upgrade Pro | Upgrade Pro |
Jun 30, 2017 | Upgrade Pro | Upgrade Pro | Upgrade Pro |
Jun 30, 2016 | Upgrade Pro | Upgrade Pro | Upgrade Pro |
Revenue Definition
Revenue, also called sales, is the amount of money a company receives from its business activities, such as sales of products or services. Revenue does not take any expenses into account and is therefore different from profits.
Full DefinitionRelated Stocks
Company Name | Revenue |
---|---|
AstraZeneca | 41.24B |
GSK plc | 31.63B |
Haleon | 11.02B |
Smith & Nephew | 4.33B |
ConvaTec Group | 1.72B |
Hikma Pharmaceuticals | 2.35B |
HUTCHMED (China) | 439.54M |
Genus | 672.80M |
ResMed News
- 2 days ago - Top 50 High-Quality Dividend Growth Stocks For October 2025 - Seeking Alpha
- 3 days ago - Why ResMed (RMD) is a Top Growth Stock for the Long-Term - Nasdaq
- 10 days ago - Zacks.com featured highlights include GE Aerospace, ResMed, Vertiv and National Fuel Gas - Nasdaq
- 11 days ago - Add These 4 GARP Stocks to Your Portfolio to Receive Handsome Returns - Nasdaq
- 12 days ago - ResMed Inc. (RMD) Presents at Bank of America Global Healthcare Conference 2025 Transcript - Seeking Alpha
- 17 days ago - ResMed (RMD) Receives 'Buy' Rating from Citigroup with $330 Price Target | RMD Stock News - GuruFocus
- 19 days ago - Resmed Announces Participation in the Bank of America Global Healthcare Conference 2025 - GlobeNewsWire
- 27 days ago - The sleep economy is 'having a moment', says medical equipment firm Resmed - CNBC